Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ: JAZZ )

133.96 -2.86 (-2.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Where Jazz Pharmaceuticals Stands With Analysts
Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Goldman Sachs lowered Casey's General Stores, Inc. (NASDAQ: 
Via Benzinga
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
10 Biggest Price Target Changes For Monday
SVB Leerink raised Natera, Inc. (NASDAQ:NTRA) pr... 
Via Benzinga
10 Biggest Price Target Changes For Friday
Piper Sandler raised Adobe Inc. (NASDAQ: ADBE) price target from $570 to $600. Adobe shares rose 3.3% to $569.50 in pre-market trading. SVB Leerink boosted Jazz... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Jazz Pharmaceuticals Updates 2021 Guidance To Include GW Pharma Acquisition
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has updated its full-year 2021 financial guidance to incorporate the GW Pharmaceuticals business, which the company... 
Via Benzinga
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (... 
Via Benzinga
Cannabis investors Discuss Strategies For 2021 In The Context Of Consolidation And Interstate Commerce
2021 seems to be the year of cannabis, as its prospects and apparent societal acceptance have dramatically changed since the industr... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Rapid Development of Cannabinoid Based Medicinal Products Reaching New Levels
Via FinancialNewsMedia
Topics Cannabis Economy
Exposures COVID-19 Cannabis Economy
6 Mid-Cap Gems for Growth at a Reasonable Price
A look at 6 attractively valued mid-cap stocks that are trading at valuations that are lower than their expected long-term growth rates. 
Via Talk Markets
Agentix Corp. (AGTX) Signs Deal With NHRI To License CBD-Based Compound To Treat Type 2 Diabetes; Adds Catalyst To Back Half Of 2021
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
This Could Be The Most Exciting Healthcare Development Of The Year
Via FinancialNewsMedia
Topics Artificial Intelligence Cannabis
Exposures Artificial Intelligence Cannabis
Medical Stocks Jazz, Horizon Are Accelerating But Iqvia Is Hitting The Brakes
Jazz Pharmaceuticals and Horizon Therapeutics are among a cadre of accelerating medical stocks, while big names like Iqvia Holdings are hitting the brakes. 
Via Investor's Business Daily
10 Biggest Price Target Changes For Monday
Morgan Stanley boosted the price target on Applied Materials, Inc. (NASDAQ: AMAT) from $113 to $137. Applied Materials shares fell 1.1% to $123.46 in pre-market trading.... 
Via Benzinga
Cramer Advises Viewers On Suncor, Jazz And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said that in the energy space he is recommending only Chevron Corporation (NYSE: CVX) and Pioneer Natural Resources... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
The Week In Cannabis: The New Tilray, Jazz-GW Pharma, Earnings, M&A, And More
This was an eventful week for the cannabis industry. On Monday, Tilray, Inc. (NASDAQ: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Closes On Acquisition Of GW Pharma, Adds CBD Drug Epidiolex To Portfolio
The biopharmaceutical company Jazz Pharmaceuticals, has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. 
Via Talk Markets
Jazz Pharmaceuticals Closes On Acquisition Of GW Pharma, Adds CBD Drug Epidiolex To Portfolio
The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH). The... 
Via Benzinga
Jazz Pharmaceuticals' Acquisition of GW Pharmaceuticals Closes
The developer of cannabis-based medications is now under new ownership. 
Via The Motley Fool
Jazz Pharmaceuticals PLC (JAZZ) Q1 2021 Earnings Call Transcript
JAZZ earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Jazz Pharma Easily Beats Earnings Views, But Sales Come In Light
Late Tuesday, Jazz Pharma reported adjusted earnings of $3.92 per share on $607.58 million in sales for its first quarter. Jazz stock was unmoved. 
Via Investor's Business Daily
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
GW Pharmaceuticals Stockholders Approve Acquisition by Jazz Pharmaceuticals
Jazz is about to get the top cannabis-derived drug on the market, in addition to a robust pipeline. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Alzheimer's Disease: 5 Stocks on Biotech Radars
What's been interesting for the past couple of years, and especially the last few months, is to watch the rise of emerging, small-cap Biotech companies trying to take on the big AD and other... 
Via Talk Markets
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.